metformin has been researched along with Granulocytic Leukemia, Chronic, Stable Phase in 1 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Metformin is a widely prescribed glucose-lowering agent for patients with diabetes and in preclinical studies, has been shown to suppress cell viability, induce apoptosis, and downregulate the mTORC1 signaling pathway in imatinib resistant CML cell lines (K562R)." | 1.72 | Impact of metformin on tyrosine kinase inhibitor response in chronic myeloid leukemia. ( Gilreath, JA; Pokorny, R; Stenehjem, DD, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pokorny, R | 1 |
| Stenehjem, DD | 1 |
| Gilreath, JA | 1 |
1 other study available for metformin and Granulocytic Leukemia, Chronic, Stable Phase
| Article | Year |
|---|---|
Impact of metformin on tyrosine kinase inhibitor response in chronic myeloid leukemia.
Topics: Adult; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloi | 2022 |